Autologous genetically modified gamma-delta T cells for glioblastoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 23 Dec 2022: Trial registered, NCT05664243
  2. 8 Sep 2023: Trial started, NCT05664243

The trials

NCT05664243: A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

State
Under way
Phase
Phase 1 and Phase 2
People
4 planned
Started
8 Sep 2023
Primary completion
Dec 2026
Arms
1) Autologous Newly Diagnosed Disease: Phase 2 Arm A
Results
None posted
  1. 23 Dec 2022: Trial registered
  2. 8 Sep 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.